Tatva Chintan Pharma Chem Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Chintan Shah
Algemeen directeur
₹13.4m
Totale compensatie
| Percentage CEO-salaris | 25.0% |
| Dienstverband CEO | 28.4yrs |
| Eigendom CEO | 23.8% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 16.1yrs |
Recente managementupdates
Recent updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26
Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Share Price Matching Investor Opinion
Apr 04These Analysts Just Made A Notable Downgrade To Their Tatva Chintan Pharma Chem Limited (NSE:TATVA) EPS Forecasts
Jan 26Tatva Chintan Pharma Chem Limited (NSE:TATVA) Analysts Are Reducing Their Forecasts For This Year
May 10Tatva Chintan Pharma Chem Limited Just Missed Revenue By 15%: Here's What Analysts Think Will Happen Next
Jul 28Getting In Cheap On Tatva Chintan Pharma Chem Limited (NSE:TATVA) Is Unlikely
Jun 17Investors Shouldn't Be Too Comfortable With Tatva Chintan Pharma Chem's (NSE:TATVA) Robust Earnings
May 03Are Investors Undervaluing Tatva Chintan Pharma Chem Limited (NSE:TATVA) By 45%?
Dec 06Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹176m |
| Jun 30 2024 | n/a | n/a | ₹261m |
| Mar 31 2024 | ₹13m | ₹3m | ₹304m |
| Dec 31 2023 | n/a | n/a | ₹377m |
| Sep 30 2023 | n/a | n/a | ₹459m |
| Jun 30 2023 | n/a | n/a | ₹452m |
| Mar 31 2023 | ₹17m | ₹5m | ₹455m |
| Dec 31 2022 | n/a | n/a | ₹460m |
| Sep 30 2022 | n/a | n/a | ₹572m |
| Jun 30 2022 | n/a | n/a | ₹825m |
| Mar 31 2022 | ₹17m | ₹5m | ₹959m |
| Dec 31 2021 | n/a | n/a | ₹995m |
| Sep 30 2021 | n/a | n/a | ₹976m |
| Jun 30 2021 | n/a | n/a | ₹687m |
| Mar 31 2021 | ₹14m | n/a | ₹523m |
| Mar 31 2020 | ₹14m | n/a | ₹378m |
| Mar 31 2019 | ₹14m | n/a | ₹205m |
Compensatie versus markt: De totale vergoeding ($USD 158.48K ) Chintan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 194.43K ).
Compensatie versus inkomsten: De vergoeding van Chintan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Chintan Shah (51 yo)
28.4yrs
Tenure
₹13,390,870
Compensatie
Mr. Chintan Nitinkumar Shah is the Managing Director and Chairman at Tatva Chintan Pharma Chem Limited and its Executive Director since June 12, 1996. He holds a bachelor’s degree in engineering, with a sp...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & MD | 28.4yrs | ₹13.39m | 23.84% ₹ 4.5b | |
| Whole Time Director | 28.4yrs | ₹13.39m | 24.01% ₹ 4.5b | |
| Whole Time Director | 28.4yrs | ₹13.39m | 24% ₹ 4.5b | |
| Non Executive Independent Director | 3.8yrs | ₹265.00k | geen gegevens | |
| Non Executive Independent Director | 3.8yrs | ₹285.00k | geen gegevens | |
| Non Executive Independent Director | 3.8yrs | ₹22.50k | geen gegevens |
16.1yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TATVA zijn ervaren en ervaren (gemiddelde ambtstermijn van 16.1 jaar).